News and Media

Press Releases

2019

July 8, 2019
Casebia Highlights Novel Research in Gene Editing Therapeutics for Hemophilia A

June 4, 2019
Casebia Announces Appointment of New SVP, Head of Technical Operations

April 24, 2019
Casebia Advances Genetic Engineering with New Tools and Techniques

2018

October 31, 2018
Casebia Therapeutics Expands Leadership Team with Addition of Dr. Adel Nada as Chief Medical Officer

May 30, 2018
Casebia Therapeutics Appoints Amy Jennings to Head its Regulatory Affairs

2017

November 13, 2017
CRISPR Therapeutics and Casebia Collaborate with CureVac on mRNA for Gene-Editing Programs

September 27, 2017
Casebia Therapeutics Announces License and Collaboration Agreements with Seattle Children’s Research Institute

September 8, 2017
Casebia Therapeutics Strengthens Leadership Team with Two Key Appointments

June 28, 2017
Casebia Therapeutics names Robin A. Walker as Vice President, Head of Legal

May 11, 2017
Casebia Therapeutics Expands Leadership Team

March 14, 2017
CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with MaxCyte

2016

November 1, 2016
Casebia Therapeutics Announces Appointment of James W. Burns, Ph.D. as President and Chief Executive Officer

In the News

2019

July 11, 2019
Boston Business Journal: Local biotechs UniQure, Casebia step up race for new hemophilia drugs

June 26, 2019
Bayer’s Can We Live Better Campaign: Are we close to a cure for hemophilia?

June 21, 2019
Seattle Children’s ‘On the Pulse’ Blog: Sonny Stays Strong as Cell Therapy for His Rare Condition Advances

May 29, 2019
Digital Biotech Podcast: Andy Scharenberg of Casebia Therapeutics

May 22, 2019
BioSpace: Casebia CEO Talks Gene Editing, Company’s Investment in Future

April 30, 2019
Genetic Engineering & Biotech News: The Darker Side of AI (Casebia’s Director of IT Emily Donlon Talks to GEN about the Importance of Cybersecurity)

April 10, 2019
In Vivo: Casebia Counts On Collaboration In Its Climb To Leadership In Gene Editing

March 25, 2019
Global Game Changers: Editing Out Genetic Disease

February 27, 2019
San Francisco Business Times: 5 startups from Mission Bay incubators to keep your eye on in 2019

February 1, 2019
STAT – First Opinion: CRISPR-Cas9 commercialization may be slowed by delivery and manufacturing challenges

January 29, 2019
The Boston Globe: State, Mass. biotech leaders team up to offer paid internships

2018

November 26, 2018
Boston Business Journal: Health Care Mass. biotech leaders voice alarm over report of first gene-edited babies

November 1, 2018
Xconomy: Adel Nada Joins Casebia as Chief Medical Officer

October 11, 2018
Pharma Intelligence: Early-Stage Cell And Gene Therapy Progress – Updates From Casebia, BlueRock, Athersys, Cynata

June 28, 2018
Labiotech.eu: The Race to Get CRISPR to the Clinic: Hope Versus Hype

May 3, 2018
Cell Stem Cell: Evolving Industry Partnerships and Investments in Cell and Gene Therapies

January 26, 2018
WIRED: What Good Is Crispr if It Can’t Get Where It Needs to Go?

2017

September 15, 2017
Boston Business Journal: Casebia Head of Legal Robin Walker named one of the 50 Most Influential People of Color in Healthcare & Life Sciences

Presentations and Abstracts

2019

International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress  |  July 8, 2019
Therapeutic Levels of FVIII Generated by CRISPR/Cas9-mediated in vivo Genome Editing in Hemophilia A Mice
Abstract  |  Presentation

ASGCT 2019  |  April 29, 2019
Engineering Potent, Small, Chimeric, Synthetic, RNA-Guided Nucleases (sRGN) from Four Uncharacterized Cas9 Genes
Abstract #135  |  Presentation

ASGCT 2019  |  April 29, 2019
Therapeutic Levels of FVIII Generated by CRISPR/Cas9-Mediated In Vivo Genome Editing in Hemophilia A Mice
Abstract #428  |  Presentation

ASGCT 2019  |  April 29, 2019
Lipid Nanoparticle Formulations Optimized for Delivery and In Vivo Gene Editing Using Novel Synthetic RNA Guided Nucleases (sRGN)
Abstract #494  |  Poster

ASGCT 2019  |  April 29, 2019
CRISPR-Based Allele-Specific Editing for the Treatment of Autosomal Dominant Retinitis Pigmentosa (ADRP)
Abstract #550  |  Poster

ASGCT 2019  |  April 29, 2019
CRISPR Cas9/gRNAs Selective Targeting of the GUCY2D Mutant Allele for Autosomal Dominant Cone-Rod Retinal Dystrophy
Abstract #561  |  Poster

ASGCT 2019  |  April 29, 2019
Gene Editing to Enforce FOXP3 Expression and a Rapamycin-Inducible IL-2 Signaling Complex in Human Primary T Cells Allows Selective Expansion of Immunosuppressive Treg-Like Cells
Abstract #660  |  Presentation

ASGCT 2019  |  April 29, 2019
Generation of Selectable, Multi-Edited Allogeneic CD3+ T Cells
Abstract #839  |  Poster

ASGCT 2019  |  April 29, 2019
Efficient and Sustained FOXP3 Locus Editing in Hematopoietic Stem Cells as a Therapeutic Approach for IPEX Syndrome
Abstract #850  |  Poster

ASGCT 2019  |  April 29, 2019
Manufacturing of Gene-Edited, Regulatory-Like, T Cells (edTreg) for Treatment of IPEX and Other Autoimmune Disorders
Abstract #857  |  Poster

ASGCT 2019  |  April 29, 2019
CRISPR/Cas9-Engineered Transgenesis of Hematopoietic Stem Cells via NHEJ-Mediated Targeted Integration Retains Engraftment Potential
Abstract #965  |  Presentation

Social Media

Local biotechs UniQure, Casebia step up race for new hemophilia drugs https://t.co/Gao2CSVaQ8

Senior Scientist Keith Abe from our #MissionBay office will be speaking next week at the @ACDbio Symposium in #SanFrancisco on the topic of ‘in vivo delivery of #Cas9 mRNA utilizing lipid nanoparticles in the mouse’ – learn more at: https://t.co/YLMBTgnR5l

See us on Twitter